ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2026
Emerging applications of traditional and generative artificial intelligence in liver transplantation.
Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Leakage-Free Survival-Modelling Benchmark for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Nested Cross-Validation Against the Milan Criteria.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Artificial intelligence (AI) has emerged as a transformative force in liver transplantation (LT), spanning patient selection, donor-recipient matching, intraoperative management, and post-transplant care. Historically, applications have relied on traditional machine learning (ML) and deep learning (DL) techniques trained on structured clinical datasets to improve risk stratification and outcome prediction. Since 2023, however, advances in generative AI (GenAI) and large language models (LLMs) have expanded the scope of AI in LT, enabling multimodal reasoning and the extraction of clinically meaningful information from unstructured data. This review synthesizes recent AI-driven developments across the LT patient journey, from advanced chronic liver disease management to long-term post-transplant outcomes. Representative applications include ML-based models to optimize treatment selection and waitlist prioritization for hepatocellular carcinoma, random forest and gradient-boosting approaches to improve donor utilization and predict graft survival, and DL-based imaging models for graft volumetry and steatosis assessment. Post-transplant innovations encompass neural network models for graft injury classification, recurrent architectures for immunosuppression dosing and fibrosis prediction, multi-task frameworks for complication risk stratification, and integrative omics-based approaches to detect rejection and dysfunction. Emerging GenAI applications include LLM-enabled digital phenotyping of social determinants of health and multi-agent simulations of transplant selection committees. Despite rapid progress, translation into routine practice remains limited by challenges in local validation, workflow integration, and infrastructure requirements. Future opportunities lie in incorporating underutilized data domains, such as psychosocial factors, -omics, and intraoperative physiologic streams, and leveraging GenAI to enhance clinical decision support, research scalability, and patient-clinician communication. AI is poised not only to refine prediction but to reshape the conceptual and operational landscape of liver transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.